Payment overview · 2025
General Payments
$57.90
3 reported records · 1 companies
Healthcare provider profile · identity verified
Charles William Ferrell, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HENNESSEY, OK · NPI 1427256106
Verified facts
What the public records show
CMS Open Payments records show Charles William Ferrell, M.D. received $57.90 in general payments during 2025 across 3 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $57.90 | 100.0% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $57.90 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $57.90 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $57.90 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 655 | 123 |
| Atorvastatin Calcium | Atorvastatin Calcium | 536 | 140 |
| Pantoprazole Sodium | Pantoprazole Sodium | 536 | 113 |
| Lisinopril | Lisinopril | 464 | 116 |
| Gabapentin | Gabapentin | 423 | 95 |
| Metformin Hcl | Metformin Hcl | 406 | 102 |
| Potassium Chloride | Potassium Chloride | 405 | 84 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 404 | 64 |
| Eliquis | Apixaban | 388 | 51 |
| Furosemide | Furosemide | 360 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 356 | 83 |
| Meloxicam | Meloxicam | 326 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 314 | 89 |
| Omeprazole | Omeprazole | 301 | 64 |
| Prednisone | Prednisone | 282 | 161 |
| Simvastatin | Simvastatin | 281 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 262 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 233 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 224 | 47 |
| Alprazolam | Alprazolam | 223 | 40 |
| Montelukast Sodium | Montelukast Sodium | 215 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 212 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 207 | 39 |
| Pregabalin | Pregabalin | 196 | 31 |
| Losartan Potassium | Losartan Potassium | 186 | 48 |
| Ibuprofen | Ibuprofen | 183 | 79 |
| Azithromycin | Azithromycin | 170 | 132 |
| Buspirone Hcl | Buspirone Hcl | 164 | 33 |
| Cefdinir | Cefdinir | 161 | 125 |
| Levofloxacin | Levofloxacin | 160 | 113 |
| Carvedilol | Carvedilol | 159 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 156 | 48 |
| Methylprednisolone | Methylprednisolone | 156 | 125 |
| Tramadol Hcl | Tramadol Hcl | 154 | 45 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 147 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 146 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 130 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 130 | 24 |
| Allopurinol | Allopurinol | 128 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 37 |
| Pioglitazone Hcl | Pioglitazone Hcl | 127 | 29 |
| Donepezil Hcl | Donepezil Hcl | 125 | 21 |
| Famotidine | Famotidine | 125 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 124 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 31 |
| Xarelto | Rivaroxaban | 121 | 18 |
| Glipizide | Glipizide | 117 | 27 |
| Mounjaro | Tirzepatide | 114 | 16 |
| Baclofen | Baclofen | 111 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 38 |
| Sertraline Hcl | Sertraline Hcl | 109 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 108 | 31 |
| Warfarin Sodium | Warfarin Sodium | 108 | 14 |
| Glipizide Er | Glipizide | 107 | 24 |
| Trazodone Hcl | Trazodone Hcl | 106 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 104 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 102 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 102 | 69 |
| Temazepam | Temazepam | 102 | 22 |
| Clonazepam | Clonazepam | 99 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 96 | 16 |
| Farxiga | Dapagliflozin Propanediol | 94 | 14 |
| Celecoxib | Celecoxib | 91 | 19 |
| Januvia | Sitagliptin Phosphate | 91 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 21 |
| Spironolactone | Spironolactone | 90 | 25 |
| Tresiba Flextouch U-200 | Insulin Degludec | 88 | 14 |
| Atenolol | Atenolol | 87 | 19 |
| Jardiance | Empagliflozin | 81 | 13 |
| Ozempic | Semaglutide | 81 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 18 |
| Aripiprazole | Aripiprazole | 75 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 70 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 17 |
| Ondansetron Odt | Ondansetron | 67 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 14 |
| Lorazepam | Lorazepam | 63 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 62 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 61 | 51 |
| Colestipol Hcl | Colestipol Hcl | 61 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 60 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 55 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | 11 |
| Fluconazole | Fluconazole | 51 | 35 |
| Enalapril Maleate | Enalapril Maleate | 50 | suppressed |
| Finasteride | Finasteride | 50 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 49 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 48 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 35 |
| Mirtazapine | Mirtazapine | 46 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 46 | 12 |
| Alendronate Sodium | Alendronate Sodium | 43 | 12 |
| Diazepam | Diazepam | 43 | 14 |
| Ezetimibe | Ezetimibe | 43 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 43 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 42 | 11 |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 25 |
| Clindamycin Hcl | Clindamycin Hcl | 34 | 28 |
| Dexlansoprazole Dr | Dexlansoprazole | 33 | suppressed |
| Gemfibrozil | Gemfibrozil | 33 | suppressed |
| Mupirocin | Mupirocin | 33 | 22 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 29 |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 32 | suppressed |
| Nystatin | Nystatin | 31 | 20 |
| Torsemide | Torsemide | 31 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | 11 |
| Methylphenidate Hcl | Methylphenidate Hcl | 30 | suppressed |
| Risperidone | Risperidone | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | 20 |
| Meclizine Hcl | Meclizine Hcl | 29 | 12 |
| Novolog | Insulin Aspart | 29 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Bumetanide | Bumetanide | 26 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Topiramate | Topiramate | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Nabumetone | Nabumetone | 21 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | 16 |
| Cephalexin | Cephalexin | 20 | 16 |
| Colchicine | Colchicine | 20 | suppressed |
| Glyburide | Glyburide | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 11 |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Sulfasalazine | Sulfasalazine | 15 | suppressed |
| Acetic Acid | Acetic Acid | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 11 |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Progesterone | Progesterone, Micronized | 12 | suppressed |
| Trandolapril | Trandolapril | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Perindopril Erbumine | Perindopril Erbumine | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tobramycin | Tobramycin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $57.90 · 3 records | ABBVIE INC. | QULIPTA, UBRELVY | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error